This question tests the non-oxidative PPP's role in ribose production. Non-oxidative PPP rearranges carbons to generate ribose-5-phosphate (R5P) without NADPH production, meeting nucleotide demands. In these dividing cells, increased non-oxidative flux provides R5P while NADPH remains unchanged, decoupling from oxidative phase. Choice D is correct because it describes increased R5P without proportional NADPH, fitting biosynthetic needs. Choice B fails by attributing NADPH to non-oxidative PPP, which lacks dehydrogenases. For similar questions, distinguish oxidative and non-oxidative branches. Verify if flux matches cellular demands like proliferation.

This question tests allosteric regulation of PFK-1 in glycolysis. PFK-1 is activated by AMP in low-energy states to promote glycolytic ATP production. In this perfusion, low ATP/high AMP (condition ii) activates PFK-1, increasing fructose-1,6-bisphosphate formation compared to high-energy condition. Choice D is correct because it links AMP activation to increased glycolytic commitment under low energy. Choice B fails by incorrectly attributing activation to ATP, which actually inhibits PFK-1. For similar questions, compare effector impacts on enzyme kinetics. Verify energy status alignment with regulatory logic.

This question tests the role of pyruvate kinase in glycolytic ATP production. Pyruvate kinase generates ATP via substrate-level phosphorylation in the final glycolytic step. In these mutant erythrocytes, pyruvate kinase deficiency impairs ATP production, contributing to hemolytic anemia despite normal PPP. Choice B is correct because it explains decreased ATP from blocked substrate-level phosphorylation. Choice A fails by suggesting increased oxidative phosphorylation, but erythrocytes lack mitochondria. For similar questions, identify ATP-yielding steps in anaerobic pathways. Verify cell-type constraints like absence of mitochondria.

This question tests understanding of the pentose phosphate pathway's oxidative phase and its role in generating NADPH. Glucose-6-phosphate dehydrogenase (G6PD) catalyzes the rate-limiting step of the oxidative PPP, converting glucose-6-phosphate to 6-phosphogluconolactone while reducing NADP+ to NADPH. A mutation decreasing G6PD catalytic efficiency would reduce NADPH production, impairing the cell's ability to regenerate reduced glutathione (GSH) from oxidized glutathione (GSSG). This leaves erythrocytes vulnerable to oxidative damage, explaining the increased methemoglobin formation under oxidant challenge. Choice A incorrectly suggests increased NADPH generation, while choice C wrongly claims the PPP produces ATP. For PPP questions, remember that the oxidative phase generates NADPH (not ATP) for reductive biosynthesis and antioxidant defense.

This question tests understanding of PFK-1 regulation by energy charge. PFK-1 is allosterically inhibited by ATP and citrate (indicators of high energy status) and activated by AMP and ADP (low energy indicators). In the fasting state with glucagon signaling, increased hepatic citrate and ATP/AMP ratio would strongly inhibit PFK-1. When PFK-1 is inhibited, its substrate fructose-6-phosphate accumulates while its product fructose-1,6-bisphosphate decreases, effectively blocking glycolytic flux. Choice B incorrectly reverses the substrate-product relationship, while choice D wrongly claims PFK-1 inhibition increases ATP yield. Remember that PFK-1 inhibition causes upstream substrate accumulation and downstream product depletion, consistent with reduced glycolytic flux during energy-replete states.

This question tests understanding of pyruvate kinase's role in glycolysis and metabolic flux. Pyruvate kinase catalyzes the final ATP-generating step of glycolysis, converting phosphoenolpyruvate (PEP) to pyruvate. When PKM2 is locked in its high-activity tetrameric state, it efficiently converts PEP to pyruvate, generating ATP and preventing accumulation of upstream glycolytic intermediates. This increased flux through the terminal glycolytic step reduces the availability of intermediates for biosynthetic pathways (like serine synthesis from 3-phosphoglycerate). Choice A incorrectly suggests PEP accumulation, while choice D wrongly connects pyruvate kinase to the PPP. For metabolic flux questions, remember that increasing enzyme activity at a regulatory step pulls substrates through that reaction, depleting upstream intermediates.

This question tests understanding of glycolytic regulation through fructose-2,6-bisphosphate (F2,6BP) signaling. F2,6BP is a potent allosteric activator of phosphofructokinase-1 (PFK-1) and inhibitor of fructose-1,6-bisphosphatase, making it a key regulator that promotes glycolysis and inhibits gluconeogenesis. When AMP levels increase (indicating low energy status), PFK-2/FBPase-2 is activated in its kinase form, producing more F2,6BP. This increased F2,6BP then activates PFK-1, leading to increased conversion of fructose-6-phosphate to fructose-1,6-bisphosphate and enhanced glycolytic flux. Choice C incorrectly suggests gluconeogenic activation, which would be inhibited by F2,6BP. To identify correct regulatory mechanisms, always consider that F2,6BP promotes glycolysis (activates PFK-1) and inhibits gluconeogenesis (inhibits FBPase-1).

This question tests the regulation of glycolysis and gluconeogenesis by fructose-2,6-bisphosphate (F2,6BP). F2,6BP is produced by the kinase activity of the bifunctional enzyme PFK-2/FBPase-2 and acts as a potent activator of PFK-1 while inhibiting FBPase-1. In this hepatocyte study with low ATP, increased PFK-2 kinase activity elevates F2,6BP, favoring glycolysis over gluconeogenesis and reducing net glucose output. Choice C is correct because increased F2,6BP enhances PFK-1 activity, promoting glycolysis and decreasing gluconeogenic flux, consistent with the observed decrease in glucose output. Choice A fails because it misattributes activation to citrate, which is not the primary regulator here and would typically signal high energy, not low. For similar questions, identify the energy status and its effect on PFK-2/FBPase-2 phosphorylation state. Always verify if the regulator aligns with promoting glycolysis in low-energy conditions.

This question tests the regulation of gluconeogenesis by allosteric inhibitors at key enzymes. AMP inhibits FBPase-1, a rate-limiting enzyme in gluconeogenesis, to prevent futile cycling during low-energy states. In this mouse model, the AMP-resistant FBPase-1 mutation allows gluconeogenesis to proceed despite high AMP, maintaining glucose output. Choice B is correct because the mutation bypasses AMP inhibition, increasing gluconeogenic flux and sustaining plasma glucose during fasting. Choice A fails due to misunderstanding that high AMP would still inhibit the mutated enzyme, but the variant is resistant. In similar questions, check for mutations altering allosteric sites and their impact on pathway flux. Verify if the change favors the pathway's continuation under inhibitory conditions.

This question tests redox regulation of lactate-pyruvate equilibrium. High cytosolic NADH favors lactate formation via LDH, reducing pyruvate available for gluconeogenesis. In these hepatocytes, increased NADH shifts equilibrium toward lactate, decreasing glucose from lactate precursors. Choice A is correct because it predicts a shift to lactate, limiting gluconeogenic substrate. Choice B fails by suggesting increased pyruvate, reversing the redox effect. In similar questions, apply mass action to reversible reactions. Check if redox state influences pathway directionality.